Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of “Moderate Buy” from Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $93.3333.

A number of equities analysts recently issued reports on the stock. Canaccord Genuity Group lowered their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Wall Street Zen cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a “hold” rating in a research report on Thursday, May 8th.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of institutional investors have recently added to or reduced their stakes in PBH. Bank of Montreal Can boosted its stake in shares of Prestige Consumer Healthcare by 15.1% in the 4th quarter. Bank of Montreal Can now owns 7,127 shares of the company’s stock valued at $557,000 after purchasing an additional 937 shares during the last quarter. Sterling Capital Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 837.1% in the 4th quarter. Sterling Capital Management LLC now owns 1,593 shares of the company’s stock valued at $124,000 after purchasing an additional 1,423 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of Prestige Consumer Healthcare by 4.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,182 shares of the company’s stock valued at $405,000 after purchasing an additional 211 shares during the last quarter. Barclays PLC boosted its stake in shares of Prestige Consumer Healthcare by 20.8% in the 4th quarter. Barclays PLC now owns 111,689 shares of the company’s stock valued at $8,721,000 after purchasing an additional 19,245 shares during the last quarter. Finally, Mariner LLC boosted its stake in shares of Prestige Consumer Healthcare by 12.6% in the 4th quarter. Mariner LLC now owns 5,492 shares of the company’s stock valued at $429,000 after purchasing an additional 615 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $65.06 on Friday. The firm has a 50 day moving average of $77.27 and a 200-day moving average of $81.58. The stock has a market capitalization of $3.20 billion, a PE ratio of 15.27, a PEG ratio of 2.04 and a beta of 0.43. Prestige Consumer Healthcare has a 12 month low of $62.95 and a 12 month high of $90.04. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). The company had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%. Prestige Consumer Healthcare’s revenue for the quarter was down 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.90 earnings per share. On average, equities research analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.